How Much Is Genetic Testing for Cancer?

The sticker price for clinical cancer genetic testing ranges from a few hundred dollars for a single-gene test to several thousand for a comprehensive multigene panel, but what you actually pay out of pocket is often far less. Laboratory patient assistance programs, insurance coverage, and financial aid initiatives have driven the real cost for many patients down to little or nothing. The gap between list price and final bill, though, depends on your insurance, the type of test ordered, and whether you qualify for assistance, so the full picture is worth understanding before you walk into a genetic counselor’s office.

What You Actually Pay vs the List Price

If you look at a testing laboratory’s published price, you might see numbers anywhere from $300 for a targeted single-gene assay up to $5,000 or more for broad next-generation sequencing panels. But those figures are increasingly disconnected from what patients hand over. A study of hereditary cancer panel testing across multiple clinical settings, including safety-net clinics serving underinsured populations, found that cost was rarely a barrier to testing. The reason: laboratories routinely help with prior authorization requests and offer payment assistance programs that bring the patient’s share down to minimal or zero expense.¹ That same research noted a broader trend: more laboratories entering the market, larger test panels becoming available, and prices falling steadily.

This does not mean cost is a non-issue. If your insurance denies coverage and you do not qualify for a lab’s assistance program, you could face the full charge. And not every lab prices the same way. Some quote a flat fee regardless of insurer; others bill insurance first and then offer a capped self-pay rate. Asking the lab and your insurer before the test is ordered remains the single most effective way to avoid a surprise bill.

Insurance Coverage and Prior Authorization

Whether your health plan covers cancer genetic testing depends on the test, your diagnosis or risk profile, and your insurer’s policies. A review of publicly available coverage policies from the largest U.S. payers found that only about a third of insurers had at least one genetic testing policy on their books. Among those that did, oncology-related tests were the most frequently addressed, but roughly half of all genetic testing policies specifically excluded certain services.² Nearly half of those policies were also out of date, meaning the insurer’s written guidelines had not kept pace with clinical recommendations.

Even when a policy exists, you may face a prior authorization requirement. A study of genetic testing in a large research cohort found that about 18% of patients had at least one insurance denial on record, with exome sequencing and microarray tests denied most often. Private insurance was roughly twice as likely to deny authorization compared with public insurance plans.³ That study focused on a pediatric genomic cohort rather than cancer specifically, but the pattern is consistent with what genetic counselors report across settings: prior authorization is common, denials happen, and appeals frequently succeed when clinical criteria are met. If your initial request is denied, ask your genetic counselor or ordering provider about the appeals process; many denials are reversed.

Single-Gene Tests vs Multigene Panels

You might be offered a test that checks for one specific gene variant, like a BRCA1 or BRCA2 mutation, or a broader panel that sequences dozens of cancer-related genes at once. The broader panel costs more up front, but the per-gene cost is lower, and you get more information in one round of testing. A systematic review of next-generation sequencing in oncology found that panel-based testing actually reduces total costs compared with running multiple single-gene assays when four or more genes need to be checked.⁴ That cost advantage grows when you account for the full picture: turnaround time, the number of clinic visits needed, and staff time spent coordinating multiple separate tests.

From a clinical standpoint, broader panels can also catch mutations that a single-gene approach would miss. One analysis of advanced non-small cell lung cancer patients found that multigene panel sequencing identified actionable mutations in an additional 8% of patients beyond what single-gene testing found.⁵ The trade-off is that lifetime total costs per patient were roughly $8,800 higher with the panel approach, driven partly by the targeted therapies that became available once those extra mutations were identified. A separate population-based study of the same cancer type found an incremental cost of about $3,500 for panel testing compared with single-gene testing, with a high probability of being cost-effective when evaluated against standard willingness-to-pay thresholds.⁶

For hereditary cancer risk assessment rather than tumor profiling, multigene panels have also become the standard. A survey of genetic counselors found that their choice of hereditary cancer panels was driven primarily by clinical indications and patient preferences rather than by cost or reimbursement considerations.⁷

Direct-to-Consumer Tests and What They Miss

Companies selling genetic tests directly to consumers offer cancer-related screening at prices well below clinical testing, sometimes under $200. These kits typically check for a handful of well-known mutations rather than sequencing entire genes. The trade-off in cost comes with a serious trade-off in accuracy. A retrospective study of direct-to-consumer (DTC) screening for hereditary breast and ovarian cancer found that for people who are not of Ashkenazi Jewish ancestry, limiting the analysis to the three common Ashkenazi founder mutations in BRCA1/2 missed more than 90% of mutations in actionable cancer risk genes. Even among Ashkenazi Jewish individuals, about 10% of BRCA1/2 mutations were missed. The study also found a false-positive rate of 69% for pathogenic variants outside the Ashkenazi BRCA1/2 founder mutations.⁸

A negative result from a DTC test, in other words, is not clinically meaningful for most people. If you have a family history that puts you at elevated risk, a DTC test cannot replace the comprehensive clinical panel your doctor would order. And a positive result from a DTC test needs to be confirmed through clinical-grade sequencing before any medical decisions are made. The cheaper price tag buys you less certainty, not equivalent certainty at a bargain.

The Separate Cost of Genetic Counseling

Genetic testing for cancer typically comes with genetic counseling, both before the test (to determine if testing is appropriate and what results might mean) and after (to interpret findings and discuss next steps). Counseling is billed as a separate service, and reimbursement patterns differ from the test itself. In one survey, genetic counselors reported that insurance covered the hereditary cancer panel about 84% of the time, but covered in-person genetic counseling only about 59% of the time. Patients were also less willing to pay out of pocket for counseling than for the test: only about 22% of patients were perceived as willing to pay more than $100 for counseling, versus 41% for the panel test.⁷

When not covered by insurance, a genetic counseling session can run from $100 to $350 or more, depending on your location and whether it is in-person or via telehealth. There is evidence that targeting counseling to patients most likely to benefit can substantially reduce these costs. A study of germline testing in metastatic prostate cancer found that applying clinical selection criteria to determine who gets counseled cut the per-patient costs of testing and post-test counseling by a factor of three compared with offering it to everyone.⁹ This does not mean counseling is optional or unimportant; it means the system works best when the right patients are matched with the right level of support.

Financial Assistance When Cost Is a Barrier

If you are uninsured, underinsured, or facing a high deductible, several avenues can reduce or eliminate your out-of-pocket costs. Most major genetic testing laboratories offer their own financial assistance or payment cap programs, and some nonprofit organizations specifically fund testing for people who meet income or insurance criteria. One well-documented example is the GIFTSS program, launched in 2009 to cover out-of-pocket expenses for cancer genetic testing among high-risk individuals with limited financial means or limited insurance coverage.¹⁰

Your ordering provider or genetic counselor is usually the best starting point. They deal with lab billing departments daily and know which labs offer patient assistance, what paperwork is required, and what income thresholds apply. Some labs will cap out-of-pocket costs at $100 or less regardless of insurance status if you apply through their program. The bottom line is that the list price should not scare you away from testing that your doctor has recommended. Ask about assistance before you decide you cannot afford it.

Testing Family Members After a Positive Result

When a cancer genetic test identifies a pathogenic variant, the next question is often whether blood relatives should be tested too. This is called cascade testing, and it is one of the most cost-effective applications of genetic testing in medicine. A cost-effectiveness analysis of BRCA testing in women with breast cancer found that testing affected women followed by cascade testing of their family members cost roughly AU$14,900 per quality-adjusted life year gained, well below standard cost-effectiveness thresholds. Each index test followed by cascade testing in relatives prevented an estimated 0.10 breast cancer events and 0.02 ovarian cancer events per family.¹¹

Once a specific familial variant is known, testing a relative for that single variant is simpler and cheaper than the original comprehensive panel. Cascade testing is typically covered by insurance when the family member meets testing criteria. A scoping review of economic evaluations found that every cascade testing study examined reported the intervention as cost-effective, and that including more relatives increased the value.¹² Starting testing earlier in life improved outcomes as well. A simulation focused on familial hypercholesterolemia, rather than cancer specifically, found that cascade testing of first-degree relatives was cost-effective when initiated before age 35, with diminishing benefits at older starting ages.¹³ The principle holds across conditions: the earlier a relative learns their status, the more time they have to benefit from surveillance or prevention.

The practical challenge is uptake. Studies estimate that the proportion of eligible relatives who actually get tested ranges from 20% to 100%, and most real-world rates sit at the lower end of that range.¹² Cost is one reason, but family dynamics, geographic distance, and lack of awareness play at least as large a role.

Costs That Come After the Test

The test itself is only the beginning. A positive result can trigger years of enhanced surveillance, preventive procedures, targeted therapies, and additional consultations. One study tracked downstream revenue generated by patients who went through hereditary cancer genetic testing and found that roughly 980 patients collectively generated over $73 million in follow-up health care after their initial genetic counseling visit.¹⁴ Even among patients who had no cancer diagnosis at the time of testing, the group generated over $11 million in downstream care, reflecting the cost of increased MRI surveillance, risk-reducing surgeries, and ongoing follow-up visits.

There is also the less obvious cost of variant reclassification. Genetic variants are classified on a spectrum from benign to pathogenic, and those classifications sometimes change as new data accumulate. When a variant gets reclassified in a way that changes your medical management, someone has to recontact you, reinterpret the result, and potentially update your care plan. One U.S.-focused analysis estimated the cost of reclassification and recontact at about $200 per case for impactful BRCA1/BRCA2 reclassifications.¹⁵ That number sounds small, but multiplied across the growing population of tested individuals, it represents a systemic cost the health care system is still figuring out how to absorb.

Who Gets Left Behind

The falling cost of genetic testing has not translated into equal access. A large study of adult patients found that Black individuals were significantly less likely to be evaluated in a genetics clinic in the first place, with odds less than 65% those of other groups. The disparity was even steeper for conditions with more subjective clinical presentations, where the odds dropped below a third. Individuals from socioeconomically disadvantaged neighborhoods were also less likely to be referred, independent of race. Strikingly, when Black patients were evaluated, they were actually more likely to undergo testing, and people from disadvantaged neighborhoods were more likely to have pathogenic variants identified, suggesting that the problem is not reluctance to test but failure to get through the door.¹⁶

Cost is one barrier, but referral patterns, provider awareness, and geographic access to genetic services all contribute. In the United States, genetic counselors are concentrated in academic medical centers and urban areas, which means rural patients and those at safety-net hospitals may face longer wait times or travel burdens even when the test itself is covered. Financial assistance programs help with the price tag but do not fix the pipeline.

The U.S. Cost Picture Compared With Other Countries

If the numbers above feel high, the international comparison provides some context. A cost-effectiveness analysis of multigene testing for all breast cancer patients found that the cost per quality-adjusted life year gained was roughly £10,500 from the UK payer perspective but about $65,700 from the U.S. payer perspective.¹⁷ The difference reflects not just the test price but the entire cost structure around it: follow-up surveillance, treatment of cancers detected, risk-reducing surgeries, and the administrative overhead of insurance billing. In single-payer systems, the economics of universal genetic testing look far more favorable simply because the downstream care costs less.

An Australian modeling study examined the costs of population-wide genomic screening for several hereditary conditions and found that screening all young adults would require an additional health system investment of about AU$622 million, but would prevent an estimated 73,000-plus disability-adjusted life years and save roughly AU$311 million in treatment costs through prevention.¹⁸ The net cost, after subtracting treatment savings, was about AU$302 million for the entire population. The implication: broad-based screening can pay for a large share of itself when the downstream savings are counted.

Legal Protections and Their Gaps

A concern that keeps some people from pursuing genetic testing is not the direct cost but the fear of what it could cost them later: higher insurance premiums, employment discrimination, or loss of coverage. The Genetic Information Nondiscrimination Act (GINA), passed in 2008, prohibits health insurers and employers from using genetic information to make coverage or hiring decisions. But GINA has significant gaps. It does not apply to life insurance, disability insurance, or long-term care insurance. If a genetic test reveals you carry a BRCA1 mutation, your health insurer cannot use that information against you, but a life insurance company can.

Awareness of GINA remains low. A survey of a diverse U.S. sample of over 1,600 people found widespread lack of understanding of the law, even among groups expected to know more about it, such as people who had undergone genetic testing or who worked in health-related fields.¹⁹ Some states have enacted their own laws that go further than GINA, extending protections to life and disability insurance. If discrimination is a concern for you, it is worth checking both federal and state-level protections before testing, and discussing them with your genetic counselor. For most people, the clinical benefits of knowing their cancer risk outweigh the insurance risks, but the calculation is personal, and the protections are not as comprehensive as many assume.